Heart failure with a preserved ejection fraction and the EMPEROR-Preserved Trial: a review of how we got here

被引：0
|
作者：
de Abreu, Tiago Tribolet [1 ]
机构：
[1] Hosp Espirito Santo Evora EPE, Serv Med, Evora, Portugal
来源：
HEART FAILURE REVIEWS | 2022年 / 27卷 / 06期
关键词：
Heart failure; Diastolic heart failure; Preserved ejection fraction; GUIDELINES; DIAGNOSIS; ECHOCARDIOGRAPHY; MANAGEMENT; COMMITTEE;
D O I：
10.1007/s10741-022-10244-8
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Heart failure with a preserved ejection fraction (HFpEF), previously known as diastolic heart failure, was first recognized more than 50 years ago. In spite of all the advances in the knowledge of HFpEF, important questions remain, namely the fact that no therapy has been shown to improve outcomes in these patients. The EMPEROR-Preserved Trial, a trial on the use of empagliflozin on patients with HFpEF, published in October 2021, was the first trial to ever show a change in outcomes in these patients. This article reviews the history of HFpEF and the problems related to its definition and diagnosis over time, and critically reviews the results of the EMPEROR-Preserved Trial in light of these.
引用
收藏
页码：2077 / 2082
页数：6
相关论文
共 50 条
  • [31] Heart failure with preserved ejection fraction: A review
    Horodinschi, Ruxandra N.
    Stoian, Anca Pantea
    Marcu, Dragos
    Costache, Raluca S.
    Diaconu, Camelia
    ROMANIAN JOURNAL OF MILITARY MEDICINE, 2018, 121 (03) : 16 - 25
  • [32] Heart Failure With Preserved Ejection Fraction: A Review
    Redfield, Margaret M.
    Borlaug, Barry A.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2023, 329 (10): : 827 - 838
  • [33] Plain language summary of the EMPEROR-Preserved study looking at the effect of empagliflozin in patients with heart failure with preserved ejection fraction, with and without diabetes
    Butler, Javed
    Filippatos, Gerasimos
    FUTURE CARDIOLOGY, 2023, 19 (15) : 723 - 733
  • [34] Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved
    Stefan D. Anker
    Javed Butler
    Muhammad Shariq Usman
    Gerasimos Filippatos
    João Pedro Ferreira
    Edimar Bocchi
    Michael Böhm
    Hans Pieter Brunner-La Rocca
    Dong-Ju Choi
    Vijay Chopra
    Eduardo Chuquiure
    Nadia Giannetti
    Juan Esteban Gomez-Mesa
    Stefan Janssens
    James L. Januzzi
    José R. González-Juanatey
    Bela Merkely
    Stephen J. Nicholls
    Sergio V. Perrone
    Ileana L. Piña
    Piotr Ponikowski
    Michele Senni
    David Sim
    Jindrich Spinar
    Iain Squire
    Stefano Taddei
    Hiroyuki Tsutsui
    Subodh Verma
    Dragos Vinereanu
    Jian Zhang
    Tomoko Iwata
    Janet M. Schnee
    Martina Brueckmann
    Stuart J. Pocock
    Faiez Zannad
    Nature Medicine, 2022, 28 : 2512 - 2520
  • [35] Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved
    Anker, Stefan D.
    Butler, Javed
    Usman, Muhammad Shariq
    Filippatos, Gerasimos
    Ferreira, Joao Pedro
    Bocchi, Edimar
    Bohm, Michael
    Brunner-La Rocca, Hans Pieter
    Choi, Dong-Ju
    Chopra, Vijay
    Chuquiure, Eduardo
    Giannetti, Nadia
    Gomez-Mesa, Juan Esteban
    Janssens, Stefan
    Januzzi, James L.
    Gonzalez-Juanatey, Jose R.
    Merkely, Bela
    Nicholls, Stephen J.
    Perrone, Sergio V.
    Pina, Ileana L.
    Ponikowski, Piotr
    Senni, Michele
    Sim, David
    Spinar, Jindrich
    Squire, Iain
    Taddei, Stefano
    Tsutsui, Hiroyuki
    Verma, Subodh
    Vinereanu, Dragos
    Zhang, Jian
    Iwata, Tomoko
    Schnee, Janet M.
    Brueckmann, Martina
    Pocock, Stuart J.
    Zannad, Faiez
    NATURE MEDICINE, 2022, 28 (12) : 2512 - +
  • [36] A mechanistic rationale for the investigation of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction. Letter regarding the article 'Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial'
    Pabel, Steffen
    Hamdani, Nazha
    Sossalla, Samuel
    EUROPEAN JOURNAL OF HEART FAILURE, 2021, 23 (05) : 841 - 841
  • [37] How to diagnose heart failure with preserved ejection fraction
    Istratoaie, Sabina
    Gargani, Luna
    Popescu, Bogdan A.
    Thomas, Liza
    Voigt, Jens-Uwe
    Donal, Erwan
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR IMAGING, 2024,
  • [38] Empagliflozin improves cardiovascular and renal outcomes in patients with preserved ejection fraction irrespective of blood pressure: the EMPEROR-Preserved trial
    Boehm, Michael
    Butler, J.
    Filippatos, G.
    Ferreira, J. P.
    Pocock, S. J.
    Abdin, A.
    Mahfoud, F.
    Brueckmann, M.
    Saloustros, I.
    Schueler, E.
    Ponikowski, P.
    Wanner, C.
    Zannad, F.
    Packer, M.
    Anker, S. D.
    EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 : 132 - 132
  • [39] Public Health Impact and Cost-Effectiveness of Empagliflozin (JARDIANCE®) in the Treatment of Patients with Heart Failure with Preserved Ejection Fraction in France, Based on the EMPEROR-Preserved Clinical Trial
    Fauchier, Laurent
    Lamblin, Nicolas
    Tardu, Jean
    Bellier, Lucile
    Groyer, Harinala
    Ittah, Deborah
    Chollet, Julien
    Linden, Stephan
    Levy, Pierre
    PHARMACOECONOMICS-OPEN, 2024, 8 (01) : 19 - 30
  • [40] Impact of empagliflozin on insulin use in patients with heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes: sub-analysis from EMPEROR-Preserved trial
    Butler, J.
    Green, J. B.
    Rosenstock, J.
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S285 - S286
12345